Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letermovir versus valganciclovir for CMV prophylaxis after adult lung transplantation
ChiCTR2600134709Phase 3Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in cytomegalovirus disease (CMV) comparing Letermovir group with Valganciclovir group (2 arms). Primary endpoint: Proportion of participants with CMV infection at 52 weeks post-transplant. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
letermovirvalganciclovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on ChiCTR2600134709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134709.